Lineage Cell Therapeutics, Inc. (LCTX) is a publicly traded Healthcare sector company. As of July 13, 2026, LCTX trades at $1.25 with a market cap of $319.10M and a P/E ratio of -4.57. LCTX moved -3.13% today. Year to date, LCTX is -20.00%; over the trailing twelve months it is +25.49%. Its 52-week range spans $0.37 to $2.09. Analyst consensus is strong buy with an average price target of $7.00. Rallies surfaces LCTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks LCTX insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $1.25 |
| Market Cap | $319.10M |
| P/E Ratio | -4.57 |
| EPS | $-0.28 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.09 |
| 52-Week Low | $0.37 |
| Volume | 355.94K |
| Avg Volume | 0 |
| Revenue (TTM) | $14.56M |
| Net Income | $-63.37M |
| Gross Margin | 0.00% |
3 analysts cover LCTX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.00.